Physician profile
Michael Gonzalez
NPI 1942536313
$2,468.33
in general payments reported to CMS, 2019-2025
21 companies · $902 in 2025
The $902 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $299 · 2022: $330 · 2023: $402 · 2024: $535 · 2025: $902.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,839.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,838.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $425.31 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $301.95 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $234.27 | 2023-2025 | |
| Amgen INC. | $224.29 | 2021-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.68 | 2024-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $180.22 | 2023-2025 | Farxiga, Breztri |
| Abbott Laboratories | $152.14 | 2024-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $111.65 | 2021-2025 | Ozempic, Rybelsus |
| Zimmer Biomet Holdings, INC. | $103.03 | 2025 | Gel-One Cross-Linked Hyaluronate |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $82.37 | 2021-2025 | Xifaxan |
| Vapotherm INC | $73.09 | 2024 | Vapotherm |
| Sanofi-Aventis U.S. LLC | $65.36 | 2021-2022 | |
| Amarin Pharma, INC. | $62.80 | 2021 | |
| Janssen Pharmaceuticals, INC | $53.23 | 2021-2024 | Xarelto |
| Abbvie INC. | $49.99 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $29.77 | 2022 | |
| Sanofi Pasteur INC. | $26.04 | 2023 | |
| Ironwood Pharmaceuticals, INC | $24.96 | 2023 | Linzess |
| Sumitomo Pharma America, INC. | $23.28 | 2025 | Gemtesa |
| Esperion Therapeutics, INC. | $22.22 | 2021 | |
| Xeris Pharmaceuticals, INC. | $20.68 | 2023 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.